Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. - Wikidata - awgldk - TriplyDB

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.

http://www.wikidata.org/entity/Q33346827

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Recurrent Glioblastoma: Where we stand Nonsurgical treatment of recurrent glioblastoma Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date EGFR-targeted therapy in malignant glioma: novel aspects and mechanisms of drug resistance.Phase I trial of verubulin (MPC-6827) plus carboplatin in patients with relapsed glioblastoma multiforme.GEINOFOTE: efficacy and safety of fotemustine in patients with high-grade recurrent gliomas and poor performance status.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Epiregulin enhances tumorigenicity by activating the ERK/MAPK pathway in glioblastoma.EGFR and EGFRvIII interact with PUMA to inhibit mitochondrial translocalization of PUMA and PUMA-mediated apoptosis independent of EGFR kinase activity.Molecular targeting of glioblastoma: Drug discovery and therapies Experimental approaches for the treatment of malignant gliomas.Small molecule kinase inhibitors in glioblastoma: a systematic review of clinical studies.An evaluation of the safety and feasibility of convection-enhanced delivery of carboplatin into the white matter as a potential treatment for high-grade glioma.Impact of imaging measurements on response assessment in glioblastoma clinical trials Targeting the RTK-PI3K-mTOR axis in malignant glioma: overcoming resistance.Innovative Therapies for Children with Cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing/refractory brain tumors Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study.Radiotherapy plus nimotuzumab or placebo in the treatment of high grade glioma patients: results from a randomized, double blind trial.Synergistic antitumor effect between gefitinib and fractionated irradiation in anaplastic oligodendrogliomas cannot be predicted by the Egfr signaling activity.Pathway inhibition: emerging molecular targets for treating glioblastoma.Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma.Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma.Radiotherapy and erlotinib combined: review of the preclinical and clinical evidence CNS Anticancer Drug Discovery and Development Conference White Paper.Combination therapy for malignant glioma based on PTEN status.Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.Treatment options for recurrent glioblastoma: pitfalls and future trends.Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02 Targeted therapy in the treatment of malignant gliomas An algorithm for chemotherapy treatment of recurrent glioma patients after temozolomide failure in the general oncology setting.Refined brain tumor diagnostics and stratified therapies: the requirement for a multidisciplinary approach.Therapeutic targeting of EGFR-activated metabolic pathways in glioblastoma.Targeted therapy in gliomas.The role of targeted therapies in the management of progressive glioblastoma : a systematic review and evidence-based clinical practice guideline.Erlotinib: early clinical development in brain cancer.State of the art and perspectives in the treatment of glioblastoma.Predictive biomarkers investigated in glioblastoma.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.

P2860

Q21133610-3C51665E-8B9D-4558-B0E8-C4DA4EFE9A4D Q26765042-CF2AF703-6DF6-43CA-99D7-861F566F083D Q26795560-1CA97E15-75E2-4776-8404-A792C57FB354 Q26822717-681DB151-5C6C-46A6-A009-BE1C22625980 Q30456087-3D0745D0-6DB0-4674-9DD0-C9ADB06518CD Q33403026-1553054F-0213-4C33-938C-BBC9B179FEF5 Q33427367-7BF9DB1B-6E72-4DFE-ADC9-2C3973BF77DE Q33747609-63D31CDB-928E-4D62-AF82-8111A3125536 Q33753468-14FD0909-0070-464A-9E83-B2AE093F4DB0 Q33872371-FE00AD86-C7FF-4FA3-A9B9-81DB49D15531 Q33911283-F9C24DBF-E781-4529-81B2-DD8AAC56D11A Q34127138-64F7E7A1-D229-4F3D-8FBE-4EA1EC05A4D8 Q34132781-B9E62439-6B38-4733-8FD6-12A79A816E37 Q34220547-89B1BDBE-0C2C-4E7E-8F9A-3A76E17BBC24 Q34331328-CED60ECE-D7BD-4D31-A513-AC38EA9D9D47 Q34447846-B76A6751-75D5-47FB-9ACC-AEF2C57A89F7 Q34480582-2BBFD128-0379-4658-878E-1838943838CF Q34480633-46AA28A0-1FE6-41A2-9BFA-39F8F34228D9 Q34778047-BF3FCA30-51E0-439A-AB56-52812C8EFC33 Q34848038-CEAB7C66-40B3-4C23-A194-FAFCF175DD30 Q35021359-C9F387A5-62DF-44AB-AFEB-FBB25549491A Q35027024-1BA28BDD-8F63-45AF-A412-C3309AE286D7 Q35642059-C048C770-FFA2-4AAA-9A6F-6B442CB5C95A Q35788884-9771D3A8-6D86-4A44-B91F-9055A78E172C Q35970960-EF47722F-9DAC-487E-BFE2-A76EC964DB9C Q36089590-2A7E6DEF-8325-4FD9-95DF-A00409E9D00E Q37316986-B0347D3C-61CA-4A5B-81ED-8546FC312493 Q37471694-3A86F4D2-A659-4FF1-B32C-4764D9F0B2A1 Q37483971-6AF5B381-5E87-40F1-86C5-2538B6813B0D Q37641248-D1B76340-CA5D-4283-9311-0971089B4D76 Q37771247-89C8107C-F975-484E-B0E0-4F6E51DD7216 Q37858468-EC81005C-E6F1-46BF-BC0F-7A88609F2603 Q38108186-1DAC5299-42D0-4772-A1EC-7F62EA414A39 Q38111449-960E5F2D-7324-43AB-9ED4-4618FA102B41 Q38186656-5FC05D59-034D-4575-8370-2C0D62B94784 Q38205134-8625B130-3EA8-4B47-9E56-854252CEBA87 Q38212394-085C6B18-BE7C-493D-BCB5-4C50FB80FE90 Q38233067-DFBDD1EE-DEF3-4B2A-B454-384C998A4C4A Q38237337-A6007642-BAAC-4102-887D-E06B171EA9C0 Q38272728-55A28F3B-7AB9-4517-85A5-E47F2BDF488B

P2860

Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma.

http://www.wikidata.org/entity/Q33346827

description

2008 nî lūn-bûn

@nan

2008 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@ast

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@en

type

label

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@ast

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@en

prefLabel

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@ast

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@en

P1433

Q33346827-F7CFF5FD-D393-4805-B64A-74775C50DC81

P1476

Q33346827-7A7B1E63-CF3D-440F-8A09-6485E5D4294B

P2093

Q33346827-02D62480-858C-4D25-B9C5-46D070423E43

Q33346827-0EF55D90-13A4-4014-A02C-C4A9128C1FF2

Q33346827-28C11329-D945-427E-B35D-D0E702BA5BE1

Q33346827-4544E746-6E3B-4A36-9EFE-46752B230C4D

Q33346827-49EC11B1-A7A3-403C-989F-152F69F47A82

Q33346827-5AE52858-08F9-4ADD-AC80-FE3565CE1BE3

Q33346827-61139007-CEDD-4423-A57C-4637156BD986

Q33346827-7052AC28-ED7C-46FE-8F4B-56F9EBD9C023

Q33346827-71342DBC-120B-4157-88EA-3E609695C53E

Q33346827-92F7FA26-AC38-4D09-9C06-0921952F0B17

P2860

Q33346827-029A8FDC-BDE4-46D5-8206-5D1523769A12

Q33346827-0678393F-3D1E-48FA-B652-09C18A381A4E

Q33346827-11521F77-D0E3-4E11-A905-4F07A5068D8B

Q33346827-2744D506-6020-4BB1-85A9-D9FF509D6A11

Q33346827-2DDC0C77-FEF2-45BD-8FE6-F49619DC1CD9

Q33346827-3EF32FF8-8449-480E-90C5-A7AE69349A79

Q33346827-467A2707-0ACE-42D7-A391-634A895BDFF8

Q33346827-481AF82E-184D-4765-94CF-06877EB05435

Q33346827-4D1DBFC1-F585-4A79-91A9-67D36259DCFE

Q33346827-536626DA-25F6-4252-8067-B2C117E2DB5C

P2888

Q33346827-107855F2-30C0-4F09-B077-E8D125AC04E1

P304

Q33346827-9F1E66A9-0608-48F9-A1F6-36222E240C46

P31

Q33346827-99D03830-E516-4022-8CD7-4B37182E8E46

P356

Q33346827-88A52C33-CE10-450D-95FC-18C9CDDD1D82

P433

Q33346827-5791D187-BB7D-4052-99FE-2B61760366FF

P478

Q33346827-EC380054-1FD6-4C85-8205-E92CBB054F1D

P577

Q33346827-9DEB4D2E-258A-4EA8-9672-B7E953FFEA89

P6179

Q33346827-81C801AD-E879-4A3A-8003-C36BC26A29E4

P698

Q33346827-2D0ABDAA-6A84-40E6-B63B-8451CB47E148

P932

Q33346827-185EDB25-6C09-4EBB-8CD8-A82C982BFF9E

P356

S11060-008-9637-Y

P1433

Journal of Neuro-Oncology

P1476

Phase II study of carboplatin ...... s with recurrent glioblastoma.

@en

P2093

C Conrad

http://www.w3.org/2001/XMLSchema#string

H Colman

http://www.w3.org/2001/XMLSchema#string

J F de Groot

http://www.w3.org/2001/XMLSchema#string

K Aldape

http://www.w3.org/2001/XMLSchema#string

K R Hess

http://www.w3.org/2001/XMLSchema#string

M D Groves

http://www.w3.org/2001/XMLSchema#string

M R Gilbert

http://www.w3.org/2001/XMLSchema#string

S Ictech

http://www.w3.org/2001/XMLSchema#string

T A Hanna

http://www.w3.org/2001/XMLSchema#string

V K Puduvalli

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.

Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials

Intravenous carboplatin for recurrent gliomas. A dose-escalating phase II trial.

Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas

Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification.

TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.

Development of the epidermal growth factor receptor inhibitor Tarceva (OSI-774).

P2888

s11060-008-9637-y

P304

89-97

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-008-9637-Y

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

90

http://www.w3.org/2001/XMLSchema#string

P577

2008-06-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026797375

http://www.w3.org/2001/XMLSchema#string

P698

18581057

http://www.w3.org/2001/XMLSchema#string

P932

6059769

http://www.w3.org/2001/XMLSchema#string